Helen Torley
PRESIDENT AND CEO at Halozyme Therapeutics Inc.
Sits on 1 board. Last updated September 27, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Halozyme Therapeutics Inc. May 1, 202599.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
| Sep 11, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −15,492 | $107.15 | $1,660,030 |
| Sep 11, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −4,508 | $107.55 | $484,826 |
| Sep 10, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
| Sep 10, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −14,588 | $107.01 | $1,561,091 |
| Sep 10, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −5,412 | $107.58 | $582,228 |
| Sep 9, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
| Sep 9, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −13,304 | $107.22 | $1,426,481 |
| Sep 9, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −6,596 | $107.82 | $711,187 |
| Sep 9, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −100 | $108.67 | $10,867 |
| Aug 19, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
| Aug 19, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −7,200 | $106.36 | $765,778 |
| Aug 19, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −9,600 | $107.22 | $1,029,350 |
| Aug 19, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −3,200 | $107.77 | $344,848 |
| Aug 18, 2026 | Halozyme Therapeutics Inc. | Option exercise | +20,000 | $18.41 | $368,200 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.